Siegfried Holding
David Nam is a Process Engineer II at Siegfried, with experience in statistical and data analysis related to clinical research involving TGF-β2 inhibitor immunotherapy for pancreatic cancer, glioma, and melanoma since August 2020. Prior to this role, David served as an Engineer at Oncotelic Inc., where responsibilities included performing stability analysis of OT-101 stock API and DP. David began a career in the pharmaceutical industry as a Translator/Interpreter at IgDraSol Inc. and participated in a successful End of Phase 2 Meeting with the FDA, translating clinical documents from Korean to English. Earlier, David served as a Sergeant in the Republic of Korea Army as an interpreter/translator. David holds a Bachelor of Science degree in Chemical Engineering from UC San Diego.
This person is not in any offices
Siegfried Holding
1 followers
Siegfried Holding AG is a Switzerland-based life sciences company and active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States and China.